Evidence map›Paper›PMID 35243139›Full record

ArticleAmerican journal of ophthalmology case reports2022

Ranizurel safety evaluation in real-world -(RaSER) study.

Ashish Sharma, Jayshree Arunaprakash, Atheeshwar Das, Ashraya Nayaka, Nilesh Kumar, Nikulaa Parachuri, Baruch D Kuppermann

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ashish SharmaLotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India.
Jayshree ArunaprakashDr Agarwals Eye Hospital, Coimbatore, TN, India.
Atheeshwar DasMedicare Eye Hospital & Laser Vision Center, Chennai, TN, India.
Ashraya NayakaThe Eye Foundation, Coimbatore, TN, India.
Nilesh KumarLotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India.
Nikulaa ParachuriLotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India.
Baruch D KuppermannGavin Herbert Eye Institute, University of California Irvine, Irvine, CA, USA.
Dr. Agarwal's Eye Hospital · INUniversity of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the early real-world clinical outcomes regarding safety and efficacy after ranizurel administration.

methodsA retrospective, consecutive, interventional, uncontrolled, multi-centre study was conducted incorporating data from four centres in India. 22 eyes with variable indications were included and all patients were treated with at least one intravitreal injection of ranizurel 0.5 mg between January 2021 and April 2021. Each patient underwent best-corrected visual acuity (BCVA) measurement with a Snellen chart (converted to LogMAR for analysis), central subfield thickness (CST) analysis with spectral-domain optical coherence tomography (SD-OCT) and intraocular pressure (IOP) measurement along with complete ophthalmic examination at baseline and the last follow-up for evaluation of adverse events after ranizurel injection.

results- None of the sites reported any signs of inflammation, vasculitis or any other ocular or systemic adverse effects in any of the cases. Mean BCVA at baseline was 0.48 ± 0.26 LogMAR (20/63) which improved significantly 0.26 ± 0.28 (20/40) at the last follow-up. (p = 0.001) Mean CST at baseline was 448.4 ± 122.9 μm which improved significantly to 328.3 ± 89.9 μm. (p = 0.001).

conclusion- The early real-world data from this limited series indicates that ranizurel is a safe alternative biologic for patients who were treatment-naive and in those who had undergone prior treatment with other anti-VEGF agents.

Indexed as

Anti-VEGFBiosimilarCME, Cystoid macular edemaCRVO, Central retinal vein occlusionDME, Diabetic macular edemaEarly experienceIRF, Intra-retinal fluidn-AMD, neovascular age related macular degenerationNSD, Neurosensory detachmentRanizuRelReal worldSRF, Sub retinal fluid

Identifiers

PMID35243139
PMCPMC8859798
OpenAlexW4210492106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.